BIOTECH, STOCKS, TECHNOLOGY
Lexaria Bioscience Corp.
Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECHTM, has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1-2 hours to just minutes, and mask unwanted tastes since 2016. DehydraTECHTM is being evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine.
Some of Lexaria's 2021 applied research and development milestones include:
- HYPER-A21-2 - DehydraTECHTM formulations deliver the strongest absorption enhancement results the company has ever recorded, at 2,708% more CBD into bloodstream during the study period than the representative industry standard MCT control formulation.
- VIRAL-C21-3 - Determined antiviral drugs processed with DehydraTECHTM were effective at inhibiting the COVID-19 SARS-CoV-2 virus.
- VIRAL-A20-2 - Circulating drug levels in the bloodstream that are twice or even three-times higher with DehydraTECHTM than without.